BEGIN:VCALENDAR
VERSION:2.0
PRODID:www.dresden-science-calendar.de
METHOD:PUBLISH
CALSCALE:GREGORIAN
X-MICROSOFT-CALSCALE:GREGORIAN
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
DTSTART:19810329T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;INTERVAL=1;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:DSC-21202
DTSTART;TZID=Europe/Berlin:20240808T130000
SEQUENCE:1723095346
TRANSP:OPAQUE
DTEND;TZID=Europe/Berlin:20240808T140000
URL:https://www.dresden-science-calendar.de/calendar/de/detail/21202
LOCATION:TUD CRTD\, Fetscherstraße 10501307 Dresden
SUMMARY:CMCB Life Sciences Seminar: Dr. Kapil Bharti\, National Eye Institu
 te Bethesda\, USA
CLASS:PUBLIC
DESCRIPTION:Speaker: \nInstitute of Speaker: \nTopics:\nWillkommen\n Locati
 on:\n  Name: TUD CRTD ()\n  Street: Fetscherstraße 105\n  City: 01307 Dre
 sden\n  Phone: +49 (0)351 458 82052\n  Fax: +49 (0)351 458 82059 \nDescrip
 tion: <p><strong>Host: </strong>Marius Ader (CRTD)</p>  <p><strong>Title: 
 </strong>“Translating RPE Biology into Disease Treatments Using Stem Cel
 ls.”</p>  <p><strong>Abstract: </strong>I have more than 15 years of exp
 erience in eye development and differentiation of retinal pigment epitheli
 um (RPE). Recently\, my lab has capitalized on induced pluripotent stem (i
 PS) cell technology to develop therapies for degenerative eye diseases. Ba
 sed on my past experience with RPE development\, we optimized a robust pro
 tocol to differentiate RPE from human iPS cells. This protocol is highly e
 fficient and reproducible in generating functional RPE cells. Combining th
 is developmental biology approach with tissue engineering\, we have grown 
 iPSC-RPE monolayers on a biodegradable scaffold and developed methods to f
 unctionally authenticate these monolayers. The resulting iPSC-RPE tissue r
 esembles native tissue in its physiological properties. This work has form
 ed the basis for a phase 1/IIa clinical trial testing the RPE-scaffold as 
 a therapeutic implant in advanced macular degeneration. In parallel\, my l
 ab also developed methods and assays to perform large-scale drug screen us
 ing iPSC-RPE grown in 384-well plates. These high throughput screens are b
 eing used to develop potential therapies for degenerative eye diseases. Wi
 th our extensive experience in iPSC-RPE\, we have derived dozens of iPS li
 nes\, which we have extensively characterized and genotyped.</p>
DTSTAMP:20260818T111435Z
CREATED:20240719T053657Z
LAST-MODIFIED:20240808T053546Z
END:VEVENT
END:VCALENDAR